Addressing the additional strategic priorities that Bayer (BAYRY) is pursuing, CEO Bill Anderson began by highlighting Pharmaceuticals’ performance. “Beyond the operational success of our Pharma business, we continue to see newsflow on our pipeline and launch assets.” The company is also making headway on its plan to improve profitability in the agricultural business, Anderson said, adding that the Crop Science Division is now in a position to streamline production and operations. The division has also reached a number of important milestones for its crop protection portfolio, with the Environmental Protection Agency proposing approval for dicamba in the United States, for instance. In addition, Bayer recently submitted icafolin, a herbicide molecule with blockbuster potential, for approval in the United States, Canada, Brazil and the European Union.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer reports Q2 core EPS EUR 1.23 vs. EUR 0.94 last year
- Bayer affirms aim to ‘significantly’ contain litigation risk by end of 2026
- Bayer’s New Study on Sevabertinib: A Potential Game-Changer for Cancer Patients with Liver Impairment
- Bayer’s SMART-Finder Study: A Closer Look at T2DM and Kidney Health
- Bayer’s FINEROD Study: Evaluating Finerenone in Real-World Settings